Atsena Therapeutics’ Post

Today we announced 12-month safety and efficacy data from the ongoing Phase I/II clinical trial of ATSN-101, our investigational #GeneTherapy for GUCY2D-associated #LeberCongenitalAmaurosis (#LCA1). ATSN-101 continues to demonstrate clinically meaningful improvements in vision at the highest dose and is well-tolerated 12 months post-treatment.   We are pleased that the 12-month data have been accepted for presentation at the 47th Annual Macula Society Meeting, which will be held February 7-10, 2024, in Palm Springs, CA.   These encouraging data and the recent #RMAT designation underscore the potential of our subretinal gene therapy to fill a significant unmet need within the LCA community.   Read more: https://lnkd.in/e5rNk-AA